Navigation Links
Study Shows That Roche's Investigational Drug for Alzheimer's Disease Removes Amyloid Plaques From the Brain

BASEL, Switzerland, Oct. 10, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.(1)

It is the first time that clinical data has been published for gantenerumab, an investigational compound with a mechanism of action targeted at the early stages of Alzheimer's disease.

Results from Phase I clinical trials and ex vivo studies demonstrated that gantenerumab treatment results in a dose-dependent reduction of brain amyloid, possibly through phagocytosis via brain microglial cells, whereas amyloid load increased in patients receiving placebo treatment.

"These results and especially the rapidity of the effects observed on amyloid removal are very encouraging and pave the way for the development of a novel treatment for Alzheimer's disease," said Luca Santarelli, Global Head of Roche Neuroscience Disease Translational Area. "Our approach is to utilize biomarkers to diagnose and treat the disease at a very early stage before significant damage to the brain has occurred."

Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody designed to bind to amyloid plaques in the brain and remove them. It is hoped that this approach will slow progression of the disease, an outcome that cannot be achieved with currently approved treatments.

"Our objective was not only to demonstrate the effects of gantenerumab on brain amyloid, but also to start elucidating its mechanism of action," added Santarelli, "this is extremely important to fully understand the compound's therapeutic potential for Alzheimer's disease."

Since it is known that amyloid accumulates in patients' brains about 15 years prior to the onset of dementia, ongoing and future clinical studies with gantenerumab will focus on Alzheimer's disease in the early or prodromal phase. It is hoped that early diagnosis and intervention, before significant damage to nerve cells has occurred, will offer optimal benefit to patients.

About the study

The effect of up to six months of treatment with gantenerumab at two different doses or placebo on brain amyloid was measured in 16 patients with mild to moderate Alzheimer's disease using positron emission tomography (PET) and the radiotracer 11C-Pittsburgh Compound B. In addition, Alzheimer's disease brain slices from an independent patient sample were incubated with gantenerumab at increasing concentrations and with human microglia in an ex vivo phagocytosis assay.

The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of gantenerumab that reduce brain amyloid and are well tolerated, with a favorable safety profile.

This is the objective of the SCarlet RoAD trial, which is set to investigate the efficacy and safety of gantenerumab in patients in the early or prodromal stage of Alzheimer's disease. Early or prodromal Alzheimer's disease is a condition in which a person's memory loss is worse than can be expected by the normal ageing process alone, even though their ability to get on with daily activities is not affected to such an extent that they would be diagnosed with dementia.

The SCarlet RoAD study is currently recruiting 360 patients in 15 countries and will look at the effects that gantenerumab has on participants' ability to remember information, to solve problems and to go about day-to-day activities. For more information:  

About gantenerumab (RG1450)

Gantenerumab is an investigational fully human anti-A beta antibody, identified and optimized by phage display technology in cooperation with MorphoSys AG, a Munich-based Biotech. It passes the blood-brain-barrier and has a high capacity to specifically bind to cerebral amyloid plaques. While the exact mechanism of antibody-mediated reduction of the amyloid burden is controversial, there is evidence that upon binding of gantenerumab to amyloid plaques brain-resident microglial cells are activated and clear plaques by a process called phagocytosis.

More information on the putative mechanism of the anti-amyloid action of gantenerumab can be found in a recent article entitled "Gantenerumab: A novel human anti-A beta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta" published by Roche scientists in the Journal of Alzheimer's Disease(2).

About Alzheimer's disease

Alzheimer's disease is the most common form of dementia. Alzheimer's disease is estimated to affect 25 million people around the world with the number of diagnosed cases expected to rise dramatically in the near future(3). It is expected that this illness will affect about 63 million people by 2030, and 114 million by 2050 worldwide(3).

In April 2011, new international guidelines on how to diagnose Alzheimer's were published for the first time in decades(4). These guidelines specifically address how to diagnose Alzheimer's in its earliest stages. They mark a major change in how experts think about and study Alzheimer's, including the need to incorporate biomarker tests.

Roche recently sponsored a website, , designed to provide healthcare professionals, patients and caregivers with information about prodromal Alzheimer's disease.

About Archives in Neurology

Archives of Neurology is a monthly peer-reviewed medical journal published by the American Medical Association. The mission of the Archives of Neurology is to publish scientific information primarily important for those physicians caring for people with neurologic disorders but also for those interested in the structure and function of the normal and diseased nervous system. These specific aims are (1) to make timely publication of original research of the nervous system, (2) to record observations of single patients or groups of patients that will provide new information and insights, (3) to report more basic research that is pertinent to the understanding of disease, (4) to introduce topics of practice, ethics, teaching, and history that are useful, (5) to provide a forum for discussion on topics that may be controversial in this field. This information will be published only after extensive peer review so that originality, clarity, and precision are insured.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

(1) Ostrowitzki, S. et al (2011) Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Archives of Neurology, 68(10)

(2) Bohrmann B et al (2011) Gantenerumab: A novel human anti-A beta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta   Journal of Alzheimer's Disease, 26, 1-21

(3) Wimo, A. et al (2003) The magnitude of dementia occurrence in the world. Alzheimer's Disease and Associated Disorders, 17 (2), 63-67

(4) US National Institutes of Health, National Institute on Aging

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
2. Hologic Announces Six-year Follow-up Results from the MammoSite Targeted Breast Irradiation Registry Study
3. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
4. FDA CONSUMER HEALTH INFORMATION -- Foreign Exporters Study Food Safety Law
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
7. Study by Ocala Oncology/The US Oncology Network Shows Use of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Improves Overall Survival
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
10. To Succeed in Crowded Market, Diabetes Manufacturers Beginning Key Launch Tactics Earlier, Study Says
11. Swype Cold & Flu Shield Significantly Reduces Occurrence of Colds in Clinical Study
Post Your Comments:
(Date:11/30/2015)... 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... Detroit Free Press as a Top Workplace , among ... to work for in 2015. ... winners annually, based on employee surveys rating company leadership, career ... are based solely on employee feedback. The survey is conducted ...
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... , November 30, 2015 global cell culture ... US$6.1 bn to US$11.3 bn by 2022 at a CAGR of ... expected to grow from its 2013 value of US$6.1 bn to ... --> Transparency Market Research has announced the release of a ... to the report, titled ,Cell Culture Market - Global Industry Analysis, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker ... order to date. , The order will be from the China Disabled Persons’ ... Implant System is an effective solution for children and adults suffering from severe ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Brooke Bennett are collaborating with brands across various categories through traditional and social ... make up an elite group of Gold Medal Moms who can connect with ...
(Date:11/30/2015)... ... December 01, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
(Date:11/30/2015)... Alexandria, VA (PRWEB) , ... November 30, 2015 ... ... Applied Research Foundation (Meso Foundation) released information for caregivers and held two webinars ... webinars are available on demand free of charge at . , ...
(Date:11/30/2015)... ... ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from INDE Broadcast ... collection of interactive exhibits within the Kids In Charge! building. In collaboration with the ... closer than ever to a range of animals as they drink, sleep and play ...
Breaking Medicine News(10 mins):